TY - JOUR AU - Zhang, Yalei AU - Shen, Jianfei AU - Simone II, Charles B. AU - Cappuzzo, Federico AU - Fong, Kwun M. AU - Rosell, Rafael AU - Chang, Joe Y. AU - Ampollini, Luca AU - Choi, J. Isabelle AU - He, Jianxing AU - Jiang, Tao AU - Lung Cancer Cooperative Group, Written on behalf of AME PY - 2018 TI - How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team JF - Journal of Thoracic Disease; Vol 10, No 6 (June 30, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Although most patients with stage I non-small cell lung cancer (NSCLC) can achieve long-term survival, some still remain at high risk of relapse (1-3). The excellent outcomes and increasing use of stereotactic ablative radiotherapy (SABR) for stage I NSCLC has recently posed a challenge to surgery (4,5). Nevertheless, lobectomy with mediastinal lymph node dissection or sampling has remained the standard of care for operable, stage I NSCLC. UR - https://jtd.amegroups.org/article/view/22209